Physician profile
Dodge A Slagle
NPI 1578570578
$27,062.68
in general payments reported to CMS, 2019-2025
23 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $3,764 · 2021: $2,276 · 2022: $249 · 2023: $385 · 2024: $72.08 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22,178.07 | 2019-2023 | Uzedy |
| Neurocrine Biosciences, INC. | $2,724.15 | 2019 | |
| Allergan, INC. | $408.46 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $306.32 | 2019-2024 | Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $162.94 | 2019-2024 | Trintellix |
| Jazz Pharmaceuticals INC. | $158.67 | 2019 | |
| Bioxcel Therapeutics, INC. | $124.01 | 2023 | Igalmi |
| E.R. Squibb & Sons, L.L.C. | $122.07 | 2025 | Cobenfy |
| Alkermes, INC. | $111.59 | 2021-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.81 | 2022-2023 | Caplyta |
| Vanda Pharmaceuticals INC. | $103.24 | 2019-2022 | |
| Lundbeck LLC | $83.41 | 2021-2023 | Rexulti |
| Brainsway USA INC | $81.90 | 2019 | |
| Abbvie INC. | $72.96 | 2021 | |
| Janssen Pharmaceuticals, INC | $65.14 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $51.14 | 2020-2022 | |
| Neuronetics, INC. | $47.55 | 2019-2024 | Neurostar Tms Therapy System |
| Acadia Pharmaceuticals INC | $37.99 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $34.73 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $28.81 | 2022-2023 | Loreev Xr |
| Merck Sharp & Dohme LLC | $18.66 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.27 | 2020 | |
| Shire North American Group INC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dodge Slagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.